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Abstract
Background: Frontline treatment of small cell lung carcinoma (SCLC) relies heavily on chemotherapeutic agents and
radiation therapy. Though SCLC patients respond well to initial cycles of chemotherapy, they eventually develop resistance.
Identification of novel therapies against SCLC is therefore imperative.
Methods and Findings: We have designed a bioluminescence-based cell viability assay for high-throughput screening of
anti-SCLC agents. The assay was first validated via standard pharmacological agents and RNA interference using two human
SCLC cell lines. We then utilized the assay in a high-throughput screen using the LOPAC
1280 compound library. The
screening identified several drugs that target classic cancer signaling pathways as well as neuroendocrine markers in SCLC.
In particular, perturbation of dopaminergic and serotonergic signaling inhibits SCLC cell viability.
Conclusions: The convergence of our pharmacological data with key SCLC pathway components reiterates the importance
of neurotransmitter signaling in SCLC etiology and points to possible leads for drug development.
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Introduction
Lung cancer is the leading cause of cancer-related mortality
worldwide, resulting in over 1.3 million deaths per year [1]. In the
United States, lung cancer incidence rates are second only to rates
for breast cancer in females and prostate cancer in males [2].
Tobacco use is the major risk factor associated with lung cancer.
Histopathological classification divides lung cancer into two main
types: small cell lung carcinoma (SCLC) and non-small cell lung
carcinoma (NSCLC). NSCLC can be further subdivided into
adenocarcinoma, squamous cell, and large cell lung carcinoma.
SCLC displays the most aggressive clinical progression of any
type of lung cancer, as demonstrated by its rapid doubling time
and early development of widespread metastases [3]. In fact,
SCLC is so aggressive that by the time it is diagnosed, metastasis
has usually already occurred such that surgical resection of tumors
is rarely an option. Hence, chemotherapy and radiation are the
treatments of choice for these patients. Most patients exhibit
robust initial response to treatment but eventually become
chemoresistant [4]. Relapses occur almost without exception and
five-year survival rates range from 31% (for patients diagnosed at
Stage I) to 2% (for patients diagnosed at Stage IV) [2]. Advances
made in the past three decades have resulted in only a slight
improvement in treatment outcome for SCLC [5]. Identification
of novel SCLC therapies is therefore of prime importance.
Cell viability assays are indispensable tools in drug discovery
efforts. Measurement of cell viability is a simple and rapid
approach for determining a cell population’s response to
endogenous factors such as hormones and growth factors as well
as external stimuli such as drugs and environmental stress [6]. A
classic approach for measuring cell viability involves the use of
vital dyes (e.g., trypan blue) for probing membrane integrity. This
method, however, is tedious and prone to experimenter bias [6].
Another traditional method relies on the reduction of tetrazolium
salts such as MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetra-
zolium bromide), resulting in the formation of colored products
that can be quantified via spectrophotometry [7]. However, such
assays have limited sensitivity, narrow dynamic ranges, and are
subject to variability [6].
Bioluminescence-based assays are a favored approach due to their
broad linearity and robustness to library compounds and complex
biological samples [8]. These assays exploit the ability of luciferase to
catalyze oxidation of the luciferin substrate, a reaction that generates
light as a by-product [8]. Light generated by this reaction has the
highest quantum efficiency of anyknown chemiluminescent reaction
[9]. Combined with low bioluminescence signals in mammalian
cells, this approach allows for highly sensitive assays.
Here, we developed a cell viability assay employing biolumi-
nescence to screen for pharmacological compounds against
SCLC. From a library of 1,280 pharmacologically active
compounds, we identified several classes of drugs that target
classic cancer signaling pathways as well as neuroendocrine
markers in SCLC.
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Ethics Statement
All animal experiments were conducted in accordance with the
guidelines for care and use of laboratory animals provided by the
National Research Council [10], as well as with an approved
animal protocol from the Institutional Animal Care and Use
Committee of the University of Massachusetts Medical School
(Assurance Number A-3306-01). Specifically, mice were exposed
to 2% isofluorane before being imaged. During imaging, mice lay
on a temperature-regulated stage and were continually exposed to
isofluorane.
Cell culture
DMS-53 and DMS-114 SCLC cell lines were acquired from
the American Type Culture Collection (ATCC) and grown in
RPMI 1640 containing 2 mM L-glutamine and 25 mM HEPES
(Cellgro), supplemented with 10% fetal bovine serum (PAA).
HEK293T cells were acquired from Open Biosystems and grown
in Dulbecco’s Modified Eagle’s Medium containing 4 mM L-
glutamine and 4.5 g/L glucose (Cellgro), supplemented with 10%
fetal bovine serum. Cells were maintained at 37uC and 8% CO2.
Cell line authentication is performed by the American Type
Culture Collection using cytochrome oxidase subunit I (COI)
analysis for interspecies identification and STR analysis (DNA
profiling) for intraspecies identification.
Cloning and Virus Production
A luciferase cassette was subcloned from pGL3-Basic (Promega)
into the multiple cloning site of the lentiviral expression vector
pLEX-MCS (Open Biosystems) using SpeI and MluI (New England
Biolabs) restriction sites. The construct, pLEX-lucSM, was
transfected into HEK293T cells for viral packaging using the
Trans-Lentiviral Packaging System (Open Biosystems). Viral
particles were harvested and used to transduce DMS-53 or
DMS-114 cells in the presence of 4 mg/mL polybrene (Sigma). To
Figure 1. Establishment of luciferase-expressing SCLC cell lines for in vitro and in vivo assays. Serial dilutions of DMS-53 luc+ and
DMS-114 luc+ cells were prepared, ranging from 0 to 1610
6 cells. Wells containing medium alone or 1610
6 DMS-53 and DMS-114 non-luciferase
expressing cells were used as negative controls (0 cells). A traditional MTT assay was performed for comparison of sensitivity and dynamic range. Cell
viability was measured using a luminometer (A–B), a spectrophotometer (C), or a Xenogen IVIS 100 imager (D–F). Colors represent clusters of CCD
pixels while color scale represents luminescence intensity from lowest (violet) to highest (red). Instrument gain was set at min=5610
7 photons/sec
to max=5610
8 photons/sec for DMS-53 luc+ in vitro (D) and at min=25610
6 photons/sec to max=25610
7 photons/sec for DMS-114 luc+ in vitro
(E). Columns represent mean values and error bars represent standard error of means (n=5 for luminometry, n=8 for spectrophotometry, n=4 for
bioluminescence imaging). For in vivo imaging (F), mice were injected subcutaneously with DMS-53 luc+ (upper left) or DMS-114 luc+ (upper
right) cells. For the lung colonization model, DMS-53 luc+ (lower left) or DMS-114 luc+ (lower right) cells were injected into the tail vein of mice.
Instrument gain was set at min=1610
5 photons/sec to max=1610
7 photons/sec for the xenograft model and at min=1610
3 photons/sec to
max=1610
4 photons/sec for the lung colonization model. RLU - relative luminescence units.
doi:10.1371/journal.pone.0024132.g001
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luc+ and DMS-114 luc+), cells were treated with 6 mg/mL
puromycin dihydrochloride for 5 days.
Luciferase Assays
Cells were lysed using 50 mL Reporter Lysis Buffer (Promega)
and placed on a shaker at room temperature for 5 minutes. To
snap-freeze, cells were placed at 280uC for 15 minutes. Cells were
then allowed to thaw and equilibrate to room temperature for
15 minutes. Plates were returned to the shaker for another 5
minutes before placing into a luminometer (Bio-Rad Lumimark).
The luminometer was set to dispense 50 mL of the luciferase
substrate (Promega Luciferase Assay Reagent). Integration time
was set for 10 seconds with a 2-second lag time. Non-luciferase
expressing cells were used as negative controls, where indicated.
MTT Assay
Cells were seeded from 0–1610
6 cells/well in black, clear
bottom 96-well assay plates and allowed to grow overnight. Cells
were then treated with 10 mL MTT Reagent (ATCC) and
incubated for 4 hours. After ensuring that purple precipitates
were visible, 100 mL of Detergent Reagent (ATCC) was added.
Samples were allowed to incubate at room temperature for
another 2 hours. Absorbance readings at 570 nm were taken using
a SpectraMax M2 microplate reader (Molecular Devices).
Bioluminescence Imaging
For imaging of luciferase-expressing cells in vitro, cells were
seeded onto black, clear bottom 96-well assay plates (Costar).
Before imaging, cell culture media were removed. The firefly
luciferase substrate D-luciferin (Gold Biotechnology) was added at
a final concentration of 150 mg/mL per well. After 15 minutes of
incubation, cells were imaged using a Xenogen IVIS 100 imager
(Caliper Life Sciences), which makes use of a supercooled charge-
coupled device (CCD) camera to detect light-emitting cells. For in
vivo work, male athymic nude mice were obtained from Charles
River Laboratories. For xenograft assays, cells were implanted
subcutaneously into the hind flanks of 6-week old mice. For the
lung colonization model, cells were injected into tail veins of 6-
week old mice. Mice were injected intraperitoneally with 150 mg/
kg D-luciferin 15 minutes prior to imaging. Quantification was
performed using the acquisition and analysis software Living
Image (Caliper Life Sciences).
Pharmacological Treatments
All drugs were purchased from Sigma. For pre-validation of the
bioluminescence assay, 1610
4DMS-53luc+andDMS-114luc+cells
were seeded inblack, clear bottom 96-wellassay plates and allowed to
grow overnight. Cells were treated with 0, 2, and 4 mM K252c
(staurosporine aglycone) for 0, 12, and 24 hours or 0, 25, and 50 mM
cis-diammineplatinum (II) chloride (cisplatin) for 0, 12, and 24 hours.
Cells were then harvested and subjected to luciferase assays.
RNA Interference
Cells were seeded in black, clear bottom 96-well assay plates and
allowed to grow overnight. Cells were transfected with 5–10 nM
of a Silencer Select Negative Control #1 or glyceraldehyde
3-phosphate dehydrogenase (GAPDH) siRNA (Applied Biosystems)
using Lipofectamine 2000 (Invitrogen) in Opti-MEM (Invitrogen).
Samples treated only with Lipofectamine 2000 were also used as
controls. After 48 hours, cells were harvested and subjected to
luciferase assays. To determine knockdown efficiency, cells were
seededinparallel onto6-wellcluster platesand transfected asabove.
After 48 hours, cells were harvested and total RNA was isolated
using an RNeasy Mini Kit (Qiagen). RNA was reverse-transcribed
using RETROscript reagents (Applied Biosystems). Samples
without reverse transcriptase were used as negative controls.
GAPDH amplicons were generated using GAPDH TaqMan assays
(Applied Biosystems) and the PRISM 7500 real-time PCR system
(Applied Biosystems). GAPDH levels were quantified using the
2
2DDCt method [11]. ß2-microglobulin was used as the endogenous
control to normalize gene expression levels.
Large-Scale Compound Screen
For primary screening, 5610
6 DMS-53+ cells were seeded in
black, clear bottom 96-well assay plates and allowed to grow
Figure 2. Bioluminescent SCLC cell lines respond to pharmacological agents in a dose- and time-dependent manner. DMS-53 luc+
and DMS-114 luc+ cells were treated with 0, 2, and 4 mM staurosporine, an apoptotic drug, for 24 hours (A,B) or with 4 mM staurosporine for 0, 12,
and 24 hours (C,D). DMS-53 luc+ and DMS-114 luc+ cells were treated with 0, 25, and 50 mM cisplatin, a chemotherapeutic drug, for 24 hours (E,F)
and 50 mM cisplatin for 0, 12, and 24 hours (G,H). Luciferase assays were then performed to measure cell viability. Data points represent mean values
and error bars represent standard error of means (n=5). RLU – relative luminescence units.
doi:10.1371/journal.pone.0024132.g002
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Pharmacologically Active Compounds, LOPAC
1280 (Sigma), were
added to each well (final concentration=50 mM in 1% DMSO).
For each plate, one column of cells (n=8 wells) was treated for
24 hours with equal concentrations of cisplatin as positive control
and another column was treated with 1% DMSO as negative
control. Tolerance of cells for 1% DMSO was confirmed prior to
screening (Fig. S1). Media aspiration and addition of compounds,
lysis buffer, and luciferase substrate were performed with a Te-Mo
(Tecan) automated system at the University of Massachusetts
Medical School Small Molecule Screening Facility. Luciferase
readouts were taken using a Victor plate reader (Perkin Elmer).
For secondary screening, selected hits from the primary screen
were retested using DMS-53 luc+ cells and further confirmed
using DMS-114 luc+ cells. For tertiary verification, DMS-53 luc+
cells were treated with increasing doses (0, 25, 50, and 100 mM) of
the representative drugs cortexolone maleate/ST-148 (Sigma) and
fluoxetine hydrochloride (Sigma) for 24 hours, followed by
luciferase assays.
Analysis
Assay quality was measured using three statistical parameters
[12]. Signal-to-background ratios (S/B) were calculated using the
equation: S/B=mmax/mmin. Signal-to-noise ratios (S/N) were
calculated using the equation: S/N=(mmax2mmin)/smin of treated
controls. For S/B and S/N, values .2 are considered acceptable.
Z9-factor values were calculated using the equation Z9 factor=
12(3smax+3smin)/|mmax2mmin|. For all equations, m represents
means and s represent standard deviations (SD). For Z9-factor
interpretation, we used the scale developed by Zhang and
colleagues [13], wherein a score of 1.0 is considered ideal; scores
between 0.5 and 1.0 represent excellent assays; scores between 0
and 0.5 represent marginal assays; and scores less than 0 represent
assays that are essentially impossible to use for screening purposes.
Figure 3. Bioluminescent SCLC cell lines respond to GAPDH depletion. DMS-53 luc+ and DMS-114 luc+ cells were treated with siRNAs
against the housekeeping gene, GAPDH. GAPDH levels after knockdown were measured using quantitative RT-PCR. Approximately 91% and 97%
knockdown was achieved for DMS-53 luc+ and DMS-114 luc+ cells, respectively (A, B). Negative controls included untreated cells (‘‘Untreated’’) and
cells treated with a negative control siRNA provided by the manufacturer (‘‘Negative Control siRNA’’, Applied Biosystems). Cell viability upon GAPDH
silencing was measured using luciferase assays (C,D). Points represent mean values and error bars represent standard error of means (n=3 for
quantitative RT-PCR, n=4 for luciferase assays).
doi:10.1371/journal.pone.0024132.g003
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Dose-Dependent Luciferase Expression
A lentiviral delivery approach was used to stably integrate a
luciferase gene into the genome of two SCLC cell lines. Serial
dilutions of these cells were then prepared to determine assay
sensitivity. DMS-53 luc+ cells could be detected above background
from as few as 10 cells using luminometry (Fig. 1A). Background
readings were taken from wells containing medium alone or wells
containing 1610
6 DMS-53 cells that do not express luciferase.
The linear range of detection for DMS-53 luc + cells was between
1610
1 to 1610
5 cells. DMS-114 luc+ cells could be detected
above background from as few as 100 cells (Fig. 1B). The linear
range of detection for these cells was between 1610
2 to 1610
5
cells. For comparison, serial dilutions of DMS-53 luc+ cells were
subjected to a traditional MTT assay (Fig. 1C). This approach
required as many as 1610
4 cells to achieve absorbance values
distinguishable from background. In addition, the linear range of
detection for the MTT assay was only between 1610
4 and 1610
5
cells/well. Importantly, the MTT assay required at least 6 hours
to run versus 45 minutes for the bioluminescence assay.
An additional advantage of using bioluminescent cell lines is
their direct applicability to in vivo bioluminescence imaging. To
confirm the utility of the luciferase-expressing cells for biolumi-
nescence imaging, the Xenogen IVIS 100 imaging system was
used, wherein the number of emitted photons is proportional to
the number of bioluminescent cells. In vitro, the linear range of
detection for DMS-53 luc+ was between 1610
4 and 1610
6 cells,
yielding bioluminescence signals between 3610
7 to 4610
9
photons/sec (Fig. 1D). In comparison, the linear range of detection
for DMS-114 luc+ was between 1610
4 and 1610
5 cells, yielding
bioluminescence signals between 2610
7 and 3610
8 photons/sec
(Fig. 1E). No luminescence signals could be detected in wells
containing 1610
6 DMS-53 or DMS-114 cells that did not express
luciferase. In vivo, DMS-53 luc+ and DMS-114 luc+ cells were used
in a xenograft tumor model and a lung colonization model
(Fig. 1F). For the xenograft model, 1610
6 DMS-53 luc+ and
DMS-114 luc+ cells were detectable 15 minutes after injection of a
luciferase substrate (upper left and right panels, respectively).
Similarly, in the lung colonization model, 1610
6 DMS-53 luc+
and DMS-114 luc+ cells were detectable in the lung area after
injection of a luciferase substrate (lower left and right panels
respectively). Mice that were implanted with cells that do not
express luciferase did not yield luminescence signals (data not
shown).
Response of Bioluminescent Cells to Pharmacological
Agents and RNA Interference
To test the hypothesis that luciferase expression reflects cell
viability, we measured the responsiveness of the engineered SCLC
cell lines to treatment with a known apoptosis-inducing agent,
staurosporine. DMS-53 luc+ and DMS-114 luc+ cells were treated
with staurosporine at varying doses (0, 2 and 4 mM) and time
points (12 and 24 hours). As shown in Fig. 2A and 2B, luciferase
activity of DMS-53 luc+ and DMS-114 luc+ cells decreased with
increasing staurosporine concentration. Correspondingly, lucifer-
ase activity for both cell lines decreased with increased exposure
time (Fig. 2C and 2D).
A similar strategy was employed to determine whether the
engineered cells would also be responsive to a known chemother-
apeutic agent, cisplatin. DMS-53 luc+ and DMS-114 luc+ cells
Figure 4. 237 compounds inhibit SCLC cell viability. DMS-53 luc+ cells were treated with compounds from the LOPAC
1280 library. Luciferase
assays were then performed to measure the effect of the compounds on cell viability. Luciferase values were normalized to the mean luciferase
values of the negative control, DMSO (dotted line). The solid red line indicates the mean value for the positive control, cisplatin. Compounds that
resulted in inhibition greater than or equal to that of cisplatin were considered hits.
doi:10.1371/journal.pone.0024132.g004
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time points (12 and 24 hours). An inverse relationship was
observed between luciferase activity and cisplatin concentration
(Fig. 2E and 2F). Similarly, luciferase activity decreased for both
cell lines with increased exposure time (Fig. 2G and 2H).
Finally, to test whether the viability of the engineered SCLC cell
lines can be modulated by genetic manipulation, cells were treated
with an siRNA against GAPDH, a known housekeeping gene.
Knockdown levels of approximately 91% and 97% were achieved
for DMS-53 luc+ and DMS-114 luc+, respectively (Fig. 3A and
3B). GAPDH knockdown resulted in decreased luciferase activity
for both cell lines (Fig. 3C and 3D).
Taken together, these results indicate that the bioluminescence
viability assay is a feasible assay for screening anti-SCLC therapies.
High-Throughput Screening (HTS) of Compound Library
The bioluminescence viability assay protocol was modified for
implementation in a high-throughput setting using the DMS-53
luc+ cell line. Assay quality was first verified using three different
statistical parameters: S/B ratio, S/N ratio, and Z9-factors (see
Materials and Methods). An S/B ratio of 3.1 and an S/N ratio of
18.6 were obtained. Both values lie within acceptable range (.2-
fold). A Z9-factor value of 0.7 was also obtained, indicating that the
assay was excellent for screening.
The assay was then used to evaluate a library of 1,280
compounds. In the primary screen, numerous compounds reduced
cell viability (Figure 4). Compounds that reduced cell viability at
an efficiency greater than or equal to cisplatin (,77% reduction)
were considered positive hits. A total of 237 hits were identified,
comprising a diverse class of compounds (Table 1). The classes
with the most number of hits ($15) included compounds directed
at phosphorylation, dopamine signaling and serotonin signaling.
Because phosphorylation is generally involved in a variety of
physiological and pathological processes, we focused secondary
screening on hits from the dopamine and serotonin classes of
compounds. We retested these compounds first using DMS-53
luc+ cells. Of the 27 dopamine compounds, 24 were confirmed
during secondary screening and of the 15 serotonin compounds,
12 were confirmed.
To ensure that reductions in viability caused by the various
compounds were not specific for DMS-53 luc+ cells, the confirmed
compounds were retested using DMS-114 luc+ cells. Of the 24
confirmed dopamine compounds, 22 caused reduction of viability
in both DMS-53 luc+ and DMS-114 luc+ cells. Of the 12
confirmed serotonin compounds, all 12 reduced viability of DMS-
53 luc+ and DMS-114 luc+ cells. Table 2 lists the compounds that
were effective in reducing viability of both cell lines along with
their specific pharmacological actions.
Finally, for tertiary verification, we performed dose-response
assays of two representative compounds, one from each class. As
shown in Fig. 5A, treatment of DMS-53 luc+ cells with increasing
doses of cortexolone maleate, a D2R dopamine receptor antago-
nist, resulted in corresponding decreases in cell viability. Similarly,
increasing concentrations of fluoxetine hydrochloride, a selective
serotonin reuptake inhibitor (SSRI), resulted in corresponding
decreases in cell viability (Fig. 5B).
Discussion
With the aim of uncovering novel therapeutic strategies against
SCLC, we developed a bioluminescence-based cell viability assay
for high-throughput screening of compound libraries. Phenotypic
assays such as the one described here expedite primary screening
of large numbers of chemicals, while limiting the use of animals in
research. In this study, we used two cell lines, DMS-53 luc+ and
DMS-114 luc+, that were originally derived from mediastinal
biopsies of SCLC patients who had not received prior therapy,
allowing delineation of specific effects of novel compounds [14].
Table 1. Classes of compounds that inhibit SCLC cell viability.
Class Number of Hits
Adenosine 4
Adrenoreceptor 10
Angiogenesis 1
Antibiotic 2
Apoptosis 6
Benzodiazepine 1
Biochemistry 9
Ca
2+ channel 10
Cannabinoid 2
Cell cycle 5
Cell stress 2
Cholinergic 7
Cytokines and growth factors 1
Cytoskeleton 4
DNA metabolism 3
Dopamine 27
GABA 5
Gene regulation 1
Glutamate 5
G-protein 4
Histamine 6
Hormone 7
Immune system 3
Intracellular calcium 4
Ion channels 2
Ion pump 5
K
+ channel 5
Leukotriene 5
Lipid 4
Lipid signaling 2
Multi-drug resistance 2
Neurodegeneration 1
Neurotransmission 7
Nitric oxide 4
Opioid 5
P2 receptor 1
Phosphatase 1
Phosphorylation 39
Serotonin 15
Sphingolipid 1
Tachykinin 3
Transcription 3
Vanilloid 2
Total=237
doi:10.1371/journal.pone.0024132.t001
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lines. Increased sensitivity of the bioluminescence assay was also
observed compared to a traditional MTT-based cell viability
assay. Moreover, a direct relationship between luminescence
signals and cell number was observed for both cell lines using two
approaches, luminometry and bioluminescence imaging. The use
of live animal bioluminescence imaging provides a more
physiologically relevant context and allows for non-invasive,
longitudinal monitoring of animals, again avoiding the use of
large numbers of animals for research. These advantages
notwithstanding, cell-based assays remain indispensable for
large-scale screens.
Prior to performing such a screen, we assessed the responsive-
ness of the two engineered cell lines to standard pharmacological
agents and RNA interference. Staurosporine, a member of the
K252 family of compounds known to inhibit protein kinases [15],
was used to show sensitivity of the engineered cells to an apoptosis-
inducing drug. Cisplatin, a platinum-containing, broad activity
anti-neoplastic and alkylating agent [16], was used to demonstrate
the sensitivity of cells to a classic chemotherapeutic agent. Finally,
RNA interference using siRNAs against GAPDH, a gene involved
in vital metabolic functions [17], illustrated the utility of these cells
for studies involving genetic treatments.
The assay was then implemented in a large-scale screen of
the LOPAC
1280 compound library. This library contains 1,280
pharmacologically active compounds. This annotated collection of
small molecule modulators and FDA-approved drugs impacts
most cellular processes and covers all major drug target classes.
The LOPAC screen serves as an excellent starting point for
validating high-throughput assays. Moreover, it potentially allows
Table 2. Pharmacological agents that target neurotransmitter signaling in SCLC.
Class Name Action Selectivity
Dopamine BP 897 Agonist D3
Chlorprothixene hydrochloride Antagonist D2
Cortexolone maleate* Antagonist D2
(6)-Butaclamol hydrochloride Antagonist D2.D1
R(+)-6-Bromo-APB hydrobromide Agonist D1
BTCP hydrochloride Blocker Reuptake
Chlorpromazine hydrochloride Antagonist -
R(2)-N-Allylnorapomorphine hydrobromide Agonist -
Dihydroergocristine methanesulfonate Agonist -
R(2)-Propylnorapomorphine hydrochloride Agonist D2
R(2)-2,10,11-Trihydroxyaporphine hybrobromide Agonist D2
GBR-12909 dihydrochloride Inhibitor Reuptake
R(2)-2,10,11-Trihydroxy-N-propylnoraporphine hydrobromide Agonist D2
Fluspirilene Antagonist D2/D1
cis-(Z)-Flupenthixol dihydrochloride Antagonist -
Fluphenazine dihydrochloride Antagonist D1/D2
GBR-12935 dihydrochloride Inhibitor Reuptake
(6)-Octoclothepin maleate Antagonist D2
Perphenazine Antagonist D2
Pimozide Antagonist D2
Prochlorperazine dimaleate Antagonist -
Thiothixene hydrochloride Antagonist D1/D2
Serotonin Amperozide hydrochloride Ligand -
Paroxetine hydrochloride hemihydrate Inhibitor Reuptake
CGS-12066A maleate Agonist 5-HT1B
S-(+)-Fluoxetine hydrochloride Inhibitor Reuptake
Fluoxetine hydrochloride* Inhibitor Reuptake
SB 228357 Antagonist 5-HT2B/2C
Metergoline Antagonist 5-HT2/5-HT1D
GR 127935 hydrochloride hydrate Antagonist 5-HT1B/1D
Sertraline hydrochloride Inhibitor Reuptake
Parthenolide Inhibitor -
Ritanserin Antagonist 5-HT2/5-HT1C
SB 224289 hydrochloride Antagonist 5-HT1B
*Representative drugs tested for tertiary verification.
- Unknown selectivity.
doi:10.1371/journal.pone.0024132.t002
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toxicity information as well as the discovery of lead structures for
drug development. Our primary screen identified several classes of
drugs that reduced SCLC cell viability (Table 1). Of these, many
have been implicated in fundamental processes associated with the
etiology of cancer, such as angiogenesis, calcium signaling, cell
cycle progression, and protein phosphorylation [18].
Interestingly, our screen identified several drug classes that
impact neuroendocrine pathways known to be involved in SCLC
pathogenesis. SCLC cells are characterized by neuroendocrine
features such as the expression of ion channels, neuropeptides, and
neurotransmitters and, as a consequence, are electrically excitable
[19]. Here, we identified drugs that target adrenergic receptors,
calcium channels, cholinergic receptors, dopamine signaling,
GABA signaling, glutamate signaling, K
+ channels, Na
+ channels,
opioid signaling and serotonin signaling [20].
We focused the follow-up screen on compounds that target
dopamine and serotonin signaling as they yielded the highest
number of hits. We did not pursue compounds in the protein
phosphorylation class given the ubiquitous role protein phosphor-
ylation plays in both normal and disease states [21,22]. The
secondary screening results essentially overlapped with those of the
primary screen, indicating the reliability of the assay. Furthermore,
the dose-dependent reduction in cell viability induced by the D2R
antagonist, cortexolone maleate, and the SSRI, fluoxetine
hydrocholoride, is consistent with the critical role of neurotrans-
mitter signaling in the pathogenesis of SCLC [23].
Dopamine signaling has previously been implicated in SCLC
[24]. In particular, the D2R agonist,bromocriptine, hasbeen shown
to have an anti-proliferative effect on SCLC cells in vitro and inhibits
growth of SCLCtumor xenografts[25]. Unexpectedly,we observed
that cortexolone maleate also has an anti-proliferative effect. These
data suggest that the effect of bromocriptine in SCLC may be
caused by D2R desensitization as opposed to agonism. In addition,
serotonin has been shown to act as a mitogenic signal in SCLC,
activating an autocrine growth loop in these cells [26,27]. However,
we found that fluoxetine hydrochloride, known to increase
serotonin levels, inhibits SCLC growth. Another SSRI, imipramine,
has previously been shown to have the same effect [28]. Taken
together, these findings also posit ligand functional selectivity, a
phenomenon wherein a drug acting through a single receptor can
act as an agonist in some cases and as an antagonist in others [29].
In conclusion, we have described a bioluminescence-based assay
for drug discovery in the field of SCLC therapeutics. Such an assay
has not been previously applied to SCLC, a disease with very poor
prognosis and limited treatment outcomes. The simplicity and
speed of the workflow we developed not only allows for routine
laboratory use but also lends itself to high-throughput applications
and adaptability to automation. We have validated this assay
against a library of pharmacologically active compounds. That
positive hits included compounds targeting classic cancer signaling
pathways suggests internal consistency. Compounds that target
neurotransmission also emerged from the screen, reflecting the
neuroendocrine nature of SCLC and underscoring the role of
neurotransmitter signaling in this disease. In particular, perturba-
tion of dopamine and serotonin signaling inhibits SCLC cell
viability, suggesting the utility of these classes of drugs as
therapeutic agents against SCLC.
Supporting Information
Figure S1 DMSO tolerance of DMS-53 luc+ cells. Cells were
treated either with 0.5% or 1% DMSO in complete medium for
24 hours. Cells in medium alone served as untreated controls. No
significant difference in cell viability was observed after DMSO
treatment. RLU – relative luminescence units.
(TIF)
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Figure 5. SCLC cells respond to cortexolone maleate and fluoxetine hydrochloride in a dose-dependent manner. DMS-53 luc+ cells
were treated with 0, 25, 50, and 100 mM cortexolone maleate (A) or fluoxetine hydrochloride (B) for 24 hours. Luciferase assays were then performed
to measure cell viability. Data points represent mean values and error bars represent standard error of means (n=8). RLU – relative luminescence
units.
doi:10.1371/journal.pone.0024132.g005
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